Paul Badawi Sells 29,244 Shares of Sight Sciences (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 29,244 shares of Sight Sciences stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $3.70, for a total value of $108,202.80. Following the sale, the chief executive officer directly owned 6,151,156 shares in the company, valued at approximately $22,759,277.20. This trade represents a 0.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Paul Badawi also recently made the following trade(s):

• On Friday, January 16th, Paul Badawi sold 22,362 shares of Sight Sciences stock. The shares were sold at an average price of $6.62, for a total value of $148,036.44.
• On Tuesday, January 6th, Paul Badawi sold 11,870 shares of Sight Sciences stock. The shares were sold at an average price of $7.48, for a total value of $88,787.60.

Sight Sciences Price Performance

Shares of SGHT stock opened at $3.52 on Friday. Sight Sciences, Inc. has a 12 month low of $2.03 and a 12 month high of $9.24. The company has a market capitalization of $190.12 million, a P/E ratio of -4.69 and a beta of 2.50. The stock has a 50 day moving average of $4.82 and a two-hundred day moving average of $5.74. The company has a current ratio of 10.22, a quick ratio of 9.52 and a debt-to-equity ratio of 0.63.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings data on Wednesday, March 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.07. The business had revenue of $20.39 million for the quarter, compared to analysts’ expectations of $20.35 million. Sight Sciences had a negative return on equity of 55.72% and a negative net margin of 49.67%. As a group, equities analysts expect that Sight Sciences, Inc. will post -0.99 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sight Sciences in a report on Monday, December 29th. Piper Sandler set a $9.00 price target on shares of Sight Sciences in a research report on Monday, January 5th. Stifel Nicolaus raised their price target on shares of Sight Sciences from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Raymond James Financial set a $9.00 price objective on Sight Sciences in a report on Monday, January 5th. Finally, William Blair reiterated an “outperform” rating on shares of Sight Sciences in a research note on Thursday, March 5th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $8.31.

Institutional Investors Weigh In On Sight Sciences

Large investors have recently made changes to their positions in the company. Long Focus Capital Management LLC lifted its holdings in Sight Sciences by 1.3% during the 3rd quarter. Long Focus Capital Management LLC now owns 3,193,305 shares of the company’s stock valued at $10,985,000 after purchasing an additional 41,797 shares during the last quarter. Vanguard Group Inc. grew its stake in Sight Sciences by 5.7% during the third quarter. Vanguard Group Inc. now owns 1,906,696 shares of the company’s stock worth $6,559,000 after buying an additional 102,609 shares during the last quarter. Americana Partners LLC increased its holdings in shares of Sight Sciences by 12.1% during the fourth quarter. Americana Partners LLC now owns 1,378,980 shares of the company’s stock worth $10,935,000 after buying an additional 149,161 shares in the last quarter. B Group Inc. raised its stake in shares of Sight Sciences by 11.6% in the second quarter. B Group Inc. now owns 930,000 shares of the company’s stock valued at $3,841,000 after acquiring an additional 96,400 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Sight Sciences by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 880,958 shares of the company’s stock valued at $6,988,000 after acquiring an additional 27,802 shares during the last quarter. Institutional investors own 55.51% of the company’s stock.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.